Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Savvides on the Utility of Immunotherapy in Lung Cancer

May 19th 2020

Panayiotis S. Savvides, MD, discusses the utility of immunotherapy in lung cancer.

FDA Grants Trastuzumab Deruxtecan Breakthrough Designation for HER2+ NSCLC

May 18th 2020

The FDA has granted a breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-positive metastatic non–small cell lung cancer.

FDA Grants Trastuzumab Deruxtecan Breakthrough Designation for HER2+ NSCLC

May 18th 2020

The FDA has granted a breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-positive metastatic non–small cell lung cancer.

Dr. Natale on the Evolution of Immunotherapy in NSCLC

May 15th 2020

Ronald B. Natale, MD, discusses the evolution of immunotherapy in advanced non–small cell lung cancer.

Regardless of Timing, Smoking Cessation Before Lung Cancer Diagnosis Shows Survival Benefit

May 14th 2020

People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.

Regardless of Timing, Smoking Cessation Before Lung Cancer Diagnosis Shows Survival Benefit

May 13th 2020

Procedural Redesign of VATS in Lung Cancer Improves Quality of Care and Reduces Cost

May 12th 2020

Through the use of value stream analysis and process design methodologies, investigators were able to reduce costs and significantly improve outcomes of patients with lung cancer who underwent video-assisted thoracic surgery.

Procedural Redesign of VATS in Lung Cancer Improves Quality of Care and Reduces Cost

May 12th 2020

FDA Approves Selpercatinib for RET+ NSCLC and Thyroid Cancers

May 9th 2020

The FDA has approved selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion–positive non–small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer.

Sintilimab Regimen Improves PFS in Frontline Squamous NSCLC

May 7th 2020

Adding the PD-1 inhibitor sintilimab injection to gemcitabine and platinum-based chemotherapy improved progression-free survival as a frontline treatment in squamous non–small cell lung cancer.

FDA Approves Capmatinib for METex14+ NSCLC

May 6th 2020

The FDA has approved capmatinib for the treatment of patients with non–small cell lung cancer.

Dr. Lopategui on the Evolution of Molecular Testing in NSCLC

May 5th 2020

Jean Lopategui, MD, discusses the evolution of molecular testing in non–small cell lung cancer.

Dr. Carbone on Acquired Resistance to Osimertinib in NSCLC

May 5th 2020

David P. Carbone, MD, PhD, discusses a study evaluating acquired resistance to osimertinib in non–small cell lung cancer.

Dr. Williams on NLR as a Prognostic Biomarker in NSCLC

May 5th 2020

Terence M. Williams, MD, PhD, discusses research examining a serum biomarker, neutrophil-to-lymphocyte ratio, in non–small cell lung cancer.

Garon Sheds Light on CNS Activity With Capmatinib in MET Exon 14+ NSCLC

May 2nd 2020

Edward B. Garon, MD, MS, discusses the importance of the GEOMETRY mono-1 study in patients with advanced NSCLC who harbor MET exon 14 skipping mutations.

Agents Targeting ROS1 Gain Traction in NSCLC

May 1st 2020

The past 2 decades have been transformative for the treatment of non–small cell lung cancer; two-thirds of patients have been found to harbor molecular drivers, and a growing proportion of these are now targetable with FDA-approved drugs.

Cell-Free DNA Detects Adjuvant MRD Positivity and Disease Relapse in NSCLC

April 29th 2020

Circulating tumor DNA may be a biomarker for the detection of postsurgical minimal residual disease and for determining the clonality of relapsing disease.

TIL Therapy Elicits Encouraging Activity in Advanced NSCLC

April 29th 2020

Adoptive cell transfer with tumor-infiltrating lymphocytes was found to be feasible, have a manageable toxicity profile, and expanded in 95% of patients with metastatic non–small cell lung cancer who had disease progression on nivolumab (Opdivo).

Poziotinib Shows Mixed Findings in Exon 20-Mutant NSCLC

April 28th 2020

Patients with pretreated non–small cell lung cancer and EGFR exon 20 insertions demonstrated a 68.7% disease control rate while on poziotinib systemic therapy.

Capmatinib Shows Clinical Meaningful Activity and Intracranial Responses in MET Exon 14+ NSCLC

April 28th 2020

Results from the GEOMETRY mono-1 study demonstrated antitumor efficacy of and deep and durable responses with capmatinib in 97 patients with advanced non–small cell lung cancer who harbor MET exon 14 mutations.